Insider Transactions in Q2 2024 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
333
-0.76%
|
$36,963
$111.15 P/Share
|
|
Jun 28
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
333
+0.75%
|
$17,982
$54.13 P/Share
|
|
Jun 21
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
74,034
-16.48%
|
$7,699,536
$104.09 P/Share
|
|
Jun 21
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
60,482
+13.81%
|
$1,874,942
$31.55 P/Share
|
|
Jun 12
2024
|
Jeffrey W. Albers |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+1.32%
|
-
|
|
Jun 12
2024
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+3.72%
|
-
|
|
Jun 12
2024
|
Lynn Seely |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+14.47%
|
-
|
|
Jun 12
2024
|
John Tsai |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+20.41%
|
-
|
|
Jun 12
2024
|
Lonnel Coats |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+14.47%
|
-
|
|
Jun 12
2024
|
Daniella Beckman |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+17.14%
|
-
|
|
Jun 12
2024
|
Habib J Dable |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+20.41%
|
-
|
|
Jun 12
2024
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+2.93%
|
-
|
|
Jun 12
2024
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
2,242
+10.94%
|
-
|
|
Jun 05
2024
|
Percy H. Carter CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
4,000
-8.72%
|
$420,000
$105.13 P/Share
|
|
Jun 04
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,424
-7.59%
|
$252,096
$104.91 P/Share
|
|
Jun 03
2024
|
Percy H. Carter CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,436
-5.04%
|
$258,216
$106.43 P/Share
|
|
Jun 03
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,922
-6.91%
|
$521,732
$106.43 P/Share
|
|
May 31
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
34,108
-14.3%
|
$3,615,448
$106.25 P/Share
|
|
May 31
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,687
+11.51%
|
$1,382,472
$56.9 P/Share
|
|
May 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,850
-2.58%
|
$408,100
$106.86 P/Share
|
|
May 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
5,856
-15.24%
|
$620,736
$106.89 P/Share
|
|
May 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,856
+12.47%
|
$228,384
$39.6 P/Share
|
|
May 08
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
28,181
+14.36%
|
$140,905
$5.34 P/Share
|
|
May 02
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-17.46%
|
$1,050,000
$105.0 P/Share
|
|
May 02
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.86%
|
$360,000
$36.05 P/Share
|
|
May 02
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,834
-10.95%
|
$188,902
$103.88 P/Share
|
|
May 02
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+9.87%
|
$99,036
$54.13 P/Share
|